Back to News
Market Impact: 0.3
Alnylam: Amvuttra Growth And Brezosiran Strengthen The Bull Case
Source: seekingalpha.com
Healthcare & BiotechCorporate EarningsCompany Fundamentals
Alnylam reported promising clinical data for investigational Huntington’s disease treatment brezosiran on October 23. Second-quarter Amvuttra sales rose 105.7% year on year to approximately $1.1 billion, although Alnylam shares remain under pressure.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
ALNY0.55
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- China industrial profits post strongest growth in three months, rising 14.4%
- China’s industrial profit growth picks up amid deepening economic divergence